Bronchiectasis is structural damage to conducting airways leading to chronic cough, sputum production, recurrent infective exacerbations, and loss of lung function. Bronchiectasis was ﬁrst described in 1819 by Laennec as an abnormal dilatation of bronchi and bronchioles caused by a vicious cycle of airway infection and inﬂammation; this deﬁnition still holds true today. Bronchiectasis is being diagnosed with increasing frequency both in the developed and underdeveloped world because of improved diagnostic techniques (high-resolution computed tomography [HRCT] scans) and awareness.
Causes of bronchiectasis may be categorized as an underlying systemic disease or anatomic abnormality, postinfectious or idiopathic. The most common causes differ by age (children vs. adults) and by country.
The most important inherited cause of bronchiectasis is cystic ﬁbrosis (CF). CF is reviewed in Plates 4-45 to 4-47; the remainder of this review focuses on non-CF bronchiectasis. Primary ciliary dyskinesia (PCD) is another well-recognized cause of bronchiectasis. PCD is an autosomal recessive, genetically heterogeneous disorder characterized by oto-sino-pulmonary disease caused by abnormal structure and function of cilia. Patients with PCD present with chronic rhinitis, recurrent otitis media and sinusitis, neonatal respiratory distress, chronic cough, and situs inversus (in 50%). Nasal nitric oxide measurements are a valuable screening tool, with low concentrations seen almost uniformly in patients with PCD. Evaluation of ciliary ultrastructure from a nasal scrape remains the best method of diagnosis. Most PCD patients (90%) have ultrastructural defects of cilia involving the outer dynein arm (ODA), inner dynein arm (IDA), or both. Genetic diagnosis is becoming increasingly possible. Mutations in DHAI1 and DNAH5 (encoding ODA proteins) are found in about 40% of PCD patients with ODA defects.
α1-antitrypsin disease is increasingly recognized as a cause of bronchiectasis. Although emphysema remains the most common pulmonary feature, 27% of patients in one series had clinically important bronchiectasis.
Immune deﬁciencies may contribute to bronchiectasis, including IgG subclass deﬁciencies; hypogammaglobulinemia; or, more rarely, chronic granulomatous disease or other causes of abnormal neutrophil adhesion, respiratory burst, and chemotaxis. HIV/AIDS is also a risk factor for bronchiectasis.
Autoimmune or immune-related diseases such as allergic bronchopulmonary aspergillosis (ABPA), collagen vascular diseases (particularly Sjögren syndrome and rheumatoid arthritis) and inﬂammatory bowel diseases may be associated with bronchiectasis.
Patients with chronic obstructive pulmonary disease may have associated bronchiectasis, affecting up to 50% of those with severe but stable disease in one series. Other anatomic lung diseases associated with diffuse bronchiectasis include tracheobronchomegaly
(Mounier-Kuhn disease), congenital cartilage deﬁciency (Williams-Campbell syndrome), and yellow nail syndrome. Obstructive airway lesions, such as endobronchial tumors, granulomatous disease, or foreign bodies, may lead to focal bronchiectasis distal to the obstruction. Other processes, such as unilateral hyper-lucent lung (Swyer-James syndrome) and pulmonary sequestration, may also lead to focal bronchiectasis.
The prevalence of postinfectious bronchiectasis plum- meted in the developed world with the introduction of antibiotic therapy for lower respiratory infections and routine childhood immunizations. However, it remains the most common cause in the developing world. Although any lower respiratory tract infection can potentially lead to bronchiectasis, infections that place individuals at greatest risk include adenovirus, pertussis, measles, and tuberculosis, as well as Klebsiella pneumoniae, Staphylococcus aureus, and Haemophilus inﬂuenzae.
Nontuberculous mycobacteria (NTM), particularly Mycobacterium avium complex (MAC), are associated with and may cause nodular bronchiectasis. MAC may present with bronchiectasis, particularly of the lingula and right middle lobe, in immunocompetent individuals without preexisting lung disease. The typical patient is an elderly, thin, white woman. A joint statement on NTM disease by the American Thoracic Society and the Infectious Disease Society of America emphasized the role of NTM in bronchiectasis.
The diagnosis of bronchiectasis should be considered in individuals presenting with chronic cough and sputum production. Other symptoms may include dyspnea, hemoptysis, and systemic symptoms such as fatigue or malaise. Among adults, bronchiectasis is more common in women than men. Idiopathic bronchiectasis occurs most frequently in middle-aged women who are lifelong nonsmokers. HRCT is the gold standard for diagnosis of bronchiectasis. Plain radiography is insufﬁciently sensitive, and contrast bronchography no longer plays a role. The extent of disease on HRCT has been correlated with functional change and clinical outcomes.
An underlying cause of bronchiectasis is more frequently identiﬁed in children than in adults. In two series from the United Kingdom, among 136 children, the cause of bronchiectasis was identiﬁed as an immunodeﬁciency in 34%, aspiration in 18%, PCD in 16%, and idiopathic in 25%. In two adult series from the United Kingdom, idiopathic bronchiectasis was diagnosed in 25% to 47% of individuals.
Examinations to consider in patients with HRCT- diagnosed bronchiectasis may include a sweat chloride test and CF genetic analysis to evaluate for CF, nasal nitric oxide and nasal scrape for PCD, immuno-deﬁciency evaluation (quantitative immunoglobulins with IgG subclasses, antibody response to vaccines with tetanus, H. inﬂuenzae), barium esophagram for gastroesophageal reﬂux, α1-antitrypsin levels, sputum culture, and acid-fast baeilli (AFB). In focal bronchiectasis, evaluation for an airway lesion should be considered.
The clinical course of non-CF bronchiectasis is highly variable, depending on the underlying cause and management. Some individuals have daily symptoms, frequent exacerbations, and progressive loss of lung function, but others have minimal daily symptoms and relative preservation of lung function. Factors associated with more rapid decline in lung function include colonization with Pseudomonas aeruginosa, more frequent exacerbations, and evidence of systemic inﬂammation.
There have been few randomized, controlled trials of therapies in individuals with bronchiectasis, partly because of the heterogeneity of the disease. Although the rationale for therapy may be similar in CF and non-CF bronchiectasis, therapies must be tested speciﬁcally in this population. For example, because in general, lung function and mortality are less impacted in non-CF bronchiectasis, therapies may be best directed to decreasing exacerbation rates rather than slowing lung function decline. Whereas rhDNase is a mainstay of therapy in CF, it has been demonstrated to have an adverse safety proﬁle in adults with bronchiectasis.
Although airway clearance techniques are a mainstay of treatment in non-CF bronchiectasis patients, there are no long-term trials in this population. There is also interest in inhaled hyperosmolar agents such as 7% saline and mannitol to rehydrate airway surface liquid. Mechanical clearance techniques, such as chest physiotherapy and ﬂutter valves, are useful but less proven in non-CF bronchiectasis as important methods of airway clearance.
Treatment of exacerbations should be undertaken with antibiotics tailored to the most recent sputum culture. The most common organisms isolated from patients with bronchiectasis include nonenteric gram-negative rods, S. aureus, and nontuberculous mycobacteria. About one-third of adults with bronchiectasis are chronically colonized with P. aeruginosa. For patients with chronic P. aeruginosa colonization, agents include intravenous antibiotics and oral ciproﬂoxacin. A recent study showed modest microbial beneﬁt but no clinical beneﬁt to the addition of inhaled tobramycin to oral ciproﬂoxacin for the treatment of acute exacerbations caused by infection with P. aeruginosa.
The role of maintenance or prophylactic antibiotics is unclear. Several small pilot studies with agents, including inhaled tobramycin, inhaled colistin, and rotating oral antibiotics, have suggested potential for microbiologic and clinical stability, but longer term studies with more attention to acquisition of resistant organisms are needed.
Inhaled corticosteroids may reduce airway inﬂammation and improve clinical outcomes in adults with bronchiectasis, but the long-term safety proﬁle is unclear. In small pilot studies, oral macrolides (erythromycin and azithromycin) may improve lung function and reduce exacerbations, but larger scale trials are needed. Caution must be taken to avoid improper treatment of unrecognized NTM infection, thus causing the emergence of resistant organisms.
Surgery may be indicated for resection of areas of focal bronchiectasis hat have led to uncontrolled infection or hemoptysis.